JP2017528734A - 診断用バイオマーカーとしての抗リンパ球自己抗体 - Google Patents

診断用バイオマーカーとしての抗リンパ球自己抗体 Download PDF

Info

Publication number
JP2017528734A
JP2017528734A JP2017527543A JP2017527543A JP2017528734A JP 2017528734 A JP2017528734 A JP 2017528734A JP 2017527543 A JP2017527543 A JP 2017527543A JP 2017527543 A JP2017527543 A JP 2017527543A JP 2017528734 A JP2017528734 A JP 2017528734A
Authority
JP
Japan
Prior art keywords
lymphocytes
lymphocyte
individual
level
lupus erythematosus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017527543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528734A5 (enExample
Inventor
アハーン，ジョセフ，エム．
リウ，チャウ−チン
マンツィ，スーザン，エム．
Original Assignee
アレゲーニー・シンガー リサーチ インスティチュート
アレゲーニー・シンガー リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレゲーニー・シンガー リサーチ インスティチュート, アレゲーニー・シンガー リサーチ インスティチュート filed Critical アレゲーニー・シンガー リサーチ インスティチュート
Publication of JP2017528734A publication Critical patent/JP2017528734A/ja
Publication of JP2017528734A5 publication Critical patent/JP2017528734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2017527543A 2014-08-08 2015-08-07 診断用バイオマーカーとしての抗リンパ球自己抗体 Pending JP2017528734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035073P 2014-08-08 2014-08-08
US62/035,073 2014-08-08
PCT/US2015/044372 WO2016023006A1 (en) 2014-08-08 2015-08-07 Anti-lymphocyte autoantibodies as diagnostic biomarkers

Publications (2)

Publication Number Publication Date
JP2017528734A true JP2017528734A (ja) 2017-09-28
JP2017528734A5 JP2017528734A5 (enExample) 2018-08-09

Family

ID=55264686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017527543A Pending JP2017528734A (ja) 2014-08-08 2015-08-07 診断用バイオマーカーとしての抗リンパ球自己抗体

Country Status (7)

Country Link
US (1) US9709564B2 (enExample)
EP (1) EP3177930A1 (enExample)
JP (1) JP2017528734A (enExample)
CN (1) CN107110861A (enExample)
BR (1) BR112017002575B1 (enExample)
RU (1) RU2017107273A (enExample)
WO (1) WO2016023006A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674543B2 (ja) 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
KR101674018B1 (ko) * 2016-05-16 2016-11-08 (주)글로리바이오텍 Cd4, cd8 세포 정보를 이용한 hiv 진단 방법
CA3022850A1 (en) 2016-05-24 2017-11-30 Allegheny-Singer Research Institute Methods and systems using c4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537449A (ja) * 2004-05-11 2007-12-20 ユニバーシティ オブ ピッツバーグ 白血球上の補体成分を測定することによる炎症性疾患の診断およびモニタリング
US20100233752A1 (en) * 2008-10-16 2010-09-16 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756571T3 (da) * 2004-04-09 2010-12-13 Univ Pittsburgh Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
WO2011099012A1 (en) * 2010-02-12 2011-08-18 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
CN102818890A (zh) * 2011-06-10 2012-12-12 苏州卫生职业技术学院 一种检测系统性红斑狼疮患者自身抗体的方法
PT2791675T (pt) * 2011-12-13 2018-07-27 Baxalta Inc Medição de autoanticorpos em condições de baixa condutividade
US20150204866A1 (en) * 2012-08-02 2015-07-23 Sense Proteomic Limited Auto-antigen biomarkers for lupus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
JP6400604B2 (ja) 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
CN103439517A (zh) * 2013-09-11 2013-12-11 河北省健海生物芯片技术有限责任公司 一种系统性红斑狼疮自身抗体检测装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537449A (ja) * 2004-05-11 2007-12-20 ユニバーシティ オブ ピッツバーグ 白血球上の補体成分を測定することによる炎症性疾患の診断およびモニタリング
US20100233752A1 (en) * 2008-10-16 2010-09-16 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C C LIU ET AL: "Antilymphocyte autoantibodies generate T cell-C4d signatures in systemic lupus erythematosus", TRANSLATIONAL RESEARCH, vol. 164, no. 6, JPN6019025334, 6 August 2014 (2014-08-06), pages 496 - 507, ISSN: 0004215924 *
C C LIU ET AL: "Complement C4d deposition on T lymphocytes: Mechanisms and significance in systemic lupus erythemato", MOLECULAR IMMUNOLOGY/ABSTRACTS, vol. 44, JPN6019025336, 1 January 2007 (2007-01-01), pages 206, ISSN: 0004068017 *

Also Published As

Publication number Publication date
US20160041164A1 (en) 2016-02-11
BR112017002575A2 (pt) 2018-01-30
WO2016023006A1 (en) 2016-02-11
RU2017107273A3 (enExample) 2019-01-18
BR112017002575B1 (pt) 2023-11-07
US9709564B2 (en) 2017-07-18
EP3177930A1 (en) 2017-06-14
CN107110861A (zh) 2017-08-29
RU2017107273A (ru) 2018-09-10

Similar Documents

Publication Publication Date Title
Laing et al. A dynamic COVID-19 immune signature includes associations with poor prognosis
JP5805368B2 (ja) Ｉｐ−１０に基づく免疫学的モニタリング
Sharma et al. High expression of CD26 accurately identifies human bacteria‐reactive MR1‐restricted MAIT cells
Zhou et al. Impact of human granulocyte and monocyte isolation procedures on functional studies
Eggleton et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects
JP4151986B2 (ja) リンパ球機能の測定方法
CN105308457B (zh) 检测供体特异性抗体的方法和用于实施所述方法的系统
Yim et al. Serum extracellular vesicles profiling is associated with COVID‐19 progression and immune responses
JP2017528734A (ja) 診断用バイオマーカーとしての抗リンパ球自己抗体
US20200011865A1 (en) Methods and kits for detecting basophil activation
US20190391148A1 (en) Flow cytometry assay methods
JP2007537449A (ja) 白血球上の補体成分を測定することによる炎症性疾患の診断およびモニタリング
Blandford et al. Analysis of plasma using flow cytometry reveals increased immune cell-derived extracellular vesicles in untreated relapsing-remitting multiple sclerosis
JP5144950B2 (ja) ナチュラルキラー活性の評価方法
WO2014160376A1 (en) Methods of detecting complement fixing and non-complement fixing antibodies and systems for practicing the same
CN105051210A (zh) 细胞结合的补体激活产物作为狼疮前期的诊断性生物标志物
JP7193054B2 (ja) 自己免疫疾患の臨床転帰を評価するための方法及びキット
US10900965B2 (en) Methods and compositions for the detection of Fc receptor binding activity of antibodies
Liu et al. Antilymphocyte autoantibodies generate T cell–C4d signatures in systemic lupus erythematosus
Aref et al. Flow cytometry detection of platelets autoantibodies in children with idiopathic thrombocytopenic purpura
Sandholm Development and evaluation of immunoassays for complement diagnostics
Drawy et al. T-cell markers in systemic lupus erythromatosus patients
Hameed Epidimilogical Study of Taxoplasmosis among Pregnant and non Pregnant in Baghdad City and its Relationship with Blood Groups.
Álvarez Jaramillo et al. Extracellular vesicles released upon stimulation with antiphospholipid antibodies: An actual direct procoagulant mechanism or a new factor in the lupus anticoagulant paradox?
DHASON et al. Prevalence of Human Leukocyte Antigen Incompatibility between Recipients of Live Relative Donor and Deceased Donor in Renal Transplantation in a Tertiary Care Centre in Southern India: A Cross-sectional Study.

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200218